BE890136A - Nouveaux agents myotonolytiques a base de 4,5,6,7-tetra-hydroisoxazolo(5,4-c)pyridine-3-ols - Google Patents

Nouveaux agents myotonolytiques a base de 4,5,6,7-tetra-hydroisoxazolo(5,4-c)pyridine-3-ols

Info

Publication number
BE890136A
BE890136A BE1/10302A BE1010302A BE890136A BE 890136 A BE890136 A BE 890136A BE 1/10302 A BE1/10302 A BE 1/10302A BE 1010302 A BE1010302 A BE 1010302A BE 890136 A BE890136 A BE 890136A
Authority
BE
Belgium
Prior art keywords
hydroisoxazolo
myotonolytic
ols
tetra
pyridine
Prior art date
Application number
BE1/10302A
Other languages
English (en)
Original Assignee
Sandoz Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Sa filed Critical Sandoz Sa
Publication of BE890136A publication Critical patent/BE890136A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BE1/10302A 1980-09-01 1981-08-28 Nouveaux agents myotonolytiques a base de 4,5,6,7-tetra-hydroisoxazolo(5,4-c)pyridine-3-ols BE890136A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8028199 1980-09-01

Publications (1)

Publication Number Publication Date
BE890136A true BE890136A (fr) 1982-03-01

Family

ID=10515772

Family Applications (1)

Application Number Title Priority Date Filing Date
BE1/10302A BE890136A (fr) 1980-09-01 1981-08-28 Nouveaux agents myotonolytiques a base de 4,5,6,7-tetra-hydroisoxazolo(5,4-c)pyridine-3-ols

Country Status (6)

Country Link
US (1) US4362731A (fr)
JP (1) JPS5777618A (fr)
AU (1) AU555504B2 (fr)
BE (1) BE890136A (fr)
IT (1) IT1138543B (fr)
PH (1) PH17018A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2219295B (en) * 1988-06-03 1992-10-07 Wyeth John & Brother Ltd Use of gamma amino butyric acid autoreceptor agonists for the manufacture of medicaments

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1488803B1 (fr) * 1993-12-28 2008-03-26 Allergan, Inc. Composante neurotoxique de la toxine botulinique pour la traitement de la dystonie cervicale
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020119168A1 (en) * 2001-02-20 2002-08-29 Rudnic Edward M. Therapeutic agent delivery
EP1648418A4 (fr) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Produit antibiotique, utilisation et formulation associees
CA2533292C (fr) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Produit antibiotique, utilisation et formulation correspondantes
EP1648415A4 (fr) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Produit antibiotique, son utilisation et sa formulation
WO2005016311A1 (fr) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Pastille robuste
CA2535398C (fr) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotique, utilisation et formulation associees
EP1658034A4 (fr) 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc Produit antibiotique, son utilisation et sa formulation
WO2005027877A1 (fr) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotique, son utilisation et sa formulation
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
AU2004324938A1 (en) * 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
ES2876350T3 (es) 2014-06-06 2021-11-12 Ovid Therapeutics Inc Métodos para aumentar la inhibición tónica y tratamiento del insomnio secundario
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
KR20240160666A (ko) 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
EP4233861A3 (fr) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions pour le traitement du tremblement essentiel
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
AU2019345312A1 (en) 2018-09-20 2021-03-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020106927A1 (fr) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol pour la réduction du risque de suicide et le soulagement rapide de la dépression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2219295B (en) * 1988-06-03 1992-10-07 Wyeth John & Brother Ltd Use of gamma amino butyric acid autoreceptor agonists for the manufacture of medicaments

Also Published As

Publication number Publication date
JPS5777618A (en) 1982-05-15
US4362731A (en) 1982-12-07
PH17018A (en) 1984-05-11
AU7478181A (en) 1982-03-11
IT1138543B (it) 1986-09-17
IT8123700A0 (it) 1981-08-31
AU555504B2 (en) 1986-09-25

Similar Documents

Publication Publication Date Title
DE3577277D1 (de) Uebungsgeraet.
FI831664A0 (fi) 1,3-dioxan-5-ylalkenoylsyror
DK587183D0 (da) 1,4-benzodiazepin-derivater
ES265246Y (es) Un pasador de sujecion.
FI850275A0 (fi) Nya 6-susbtituerade furo-(3,4-c) -pyridinderivat.
NO160564C (no) Treningsapparat.
IT1194789B (it) 25-idrossi-26,26,26,27,27,27-esafluorocolecalciferolo
DK284481A (da) 10-(1,2-propadiennyl) steroider
DE3166949D1 (de) Antiinflammatory 4,5-diaryl-alpha-polyfluoroalkyl-1h-imidazole-2-methanamines
TR20923A (tr) Izoksazolilbenzamidler
FI854178L (fi) 1,2,4-triazolo-karbamat och dess syraadditionssalter, foerfarande foer deras framstaellning och laekemedel.
IT8121126A0 (it) 1 alfa-idrossi-2beta-fluorocolecalciferolo.
DK155594C (da) 3,3-dimethyl-1-phenoxybutan-2-oler
FI811967L (fi) 2,3-bis-hydroxibenzylderivat
DE3365097D1 (de) 6,7-dihydro-7,7-disubstituted-khellins
ES262334Y (es) "un peine".
FI812210L (fi) Stabiliserade 1,1,1-trikloretansammansaettningar
IT8121847A0 (it) Agenti antidiarroici.
IT1172389B (it) 2,2,2-trialogeno-1-(trialogenometil)etiliden-bis-benzen-tioli
DE3576334D1 (de) 1,2,3,3a,8,8a-hexahydro-indeno-(1,2-c)pyrrde.
DE3360666D1 (de) 2,6-dicyanoanilines
DE3175752D1 (de) 1,3-dihalopropan-2-ols
FI810242L (fi) 1,3-diformyloxi-2-brom-nitropropan
FI854026A0 (fi) 2-fenylpyrano/2,3-b/pyridiner.
IT1189011B (it) 1,4;3,6-dinanidro-2,5-diazido-2,5-dideossi-esitoli

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: SANDOZ S.A.

Effective date: 19870831